189 related articles for article (PubMed ID: 17806135)
1. Rosiglitazone and cardiovascular risk.
Diamond GA; Kaul S
N Engl J Med; 2007 Aug; 357(9):938-9; author reply 939-40. PubMed ID: 17806135
[No Abstract] [Full Text] [Related]
2. Rosiglitazone and cardiovascular risk.
Bracken MB
N Engl J Med; 2007 Aug; 357(9):937-8; author reply 939-40. PubMed ID: 17761600
[No Abstract] [Full Text] [Related]
3. Rosiglitazone and cardiovascular risk.
Mannucci E; Monami M; Marchionni N
N Engl J Med; 2007 Aug; 357(9):938; author reply 939-40. PubMed ID: 17806136
[No Abstract] [Full Text] [Related]
4. Rosiglitazone: a thunderstorm from scarce and fragile data.
Mulrow CD; Cornell J; Localio AR
Ann Intern Med; 2007 Oct; 147(8):585-7. PubMed ID: 17938398
[No Abstract] [Full Text] [Related]
5. The record on rosiglitazone and the risk of myocardial infarction.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
[No Abstract] [Full Text] [Related]
6. Analytical issues regarding rosiglitazone meta-analysis.
Claggett B; Wei LJ
Arch Intern Med; 2011 Jan; 171(2):179-80; author reply 180. PubMed ID: 21263111
[No Abstract] [Full Text] [Related]
7. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.
Diamond GA; Bax L; Kaul S
Ann Intern Med; 2007 Oct; 147(8):578-81. PubMed ID: 17679700
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone and cardiovascular risk.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
[No Abstract] [Full Text] [Related]
9. Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.
Boyle P
South Med J; 2007 Nov; 100(11):1063-4. PubMed ID: 17984728
[No Abstract] [Full Text] [Related]
10. Faster publication isn't always better.
Fuster V; Farkouh ME
Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
[No Abstract] [Full Text] [Related]
11. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
[No Abstract] [Full Text] [Related]
12. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
Hiatt WR; Kaul S; Smith RJ
N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
[No Abstract] [Full Text] [Related]
13. Rosiglitazone and cardiovascular risk.
Kaul S; Diamond GA
Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
[TBL] [Abstract][Full Text] [Related]
14. The rosiglitazone meta-analysis.
McCullough PA; Lepor NE
Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
[No Abstract] [Full Text] [Related]
15. Rosiglitazone--continued uncertainty about safety.
Drazen JM; Morrissey S; Curfman GD
N Engl J Med; 2007 Jul; 357(1):63-4. PubMed ID: 17551160
[No Abstract] [Full Text] [Related]
16. Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
Marx N
Diab Vasc Dis Res; 2007 Jun; 4(2):80-1. PubMed ID: 17654439
[No Abstract] [Full Text] [Related]
17. Rosiglitazone and cardiovascular disease: a diabetologist's perspective.
Grant PJ
Diab Vasc Dis Res; 2007 Jun; 4(2):75-6. PubMed ID: 17654437
[No Abstract] [Full Text] [Related]
18. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
Nissen SE; Wolski K
N Engl J Med; 2007 Jun; 356(24):2457-71. PubMed ID: 17517853
[TBL] [Abstract][Full Text] [Related]
19. Perspective: effect of rosiglitazone on cardiovascular outcomes.
Nissen SE
Curr Cardiol Rep; 2007 Sep; 9(5):343-4. PubMed ID: 17877927
[No Abstract] [Full Text] [Related]
20. The Avandia debacle: methodology and practical importance of the findings.
Meneghini LF; Florez H; Tamariz L
South Med J; 2007 Nov; 100(11):1062-3. PubMed ID: 17984727
[No Abstract] [Full Text] [Related]
[Next] [New Search]
